SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

ONCY

Oncolytics Biotech, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 17h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor the ASH presentation on December 12, 2026 for any clinical response rates or survival data that could inform the registrational path. The current data are mechanistic and do not change the near-term outlook.

DirectionNeutral
Confidencemedium
Horizonweeks

pelareorep

◆ Mixed Named in this press release
Impact
Phase
Phase 2/3
Time to market
At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
Next catalyst
None dated

What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.4077
T+0 close · Nov 9, 2026 · via day close
Latest settled
−16.63%
T+5 · $0.3399
Vs SPY
−14.94%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.4077entry
  2. T+1 · 7d ago −6.35%α −5.98% · $0.3818
  3. T+5 · 20h ago −16.63%α −14.94% · $0.3399
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech announced translational data from a Phase 1b/2 trial of pelareorep in heavily pretreated relapsed/refractory multiple myeloma, to be presented at the ASH annual meeting. The data show immune activation and direct tumor effects, but this is an early-stage, non-regulatory update with no new clinical endpoints or financial guidance.

Key Facts

  • Translational data from Phase 1b/2 trial in relapsed/refractory multiple myeloma patients with median 4 prior lines of therapy
  • Data show enhanced antigen-presenting activity, increased apoptotic signaling, and expansion of CD8 effector memory T cells
  • Clinical responders had greater CD8 EM T cell expansion and lower T cell exhaustion vs non-responders
  • Data to be presented at ASH annual meeting on December 12, 2026 (abstract #2183)
  • Pelareorep has Fast Track designation for colorectal, anal, and pancreatic cancer but not for multiple myeloma

Financial Impact

No financial figures stated; early-stage translational data with no revenue or cost implications disclosed

Risk Factors

  • Early-stage translational data may not translate to clinical benefit in larger trials
  • No regulatory milestone or approval decision; multiple myeloma is not a Fast Track indication for pelareorep
  • Company is clinical-stage with no approved products; relies on partnerships and capital markets for funding

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398560

Track record

32 reports on ONCY

Performance horizon

3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  3. Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  5. Nov 9, 20267d ago Press Release Neutral 3/10 Viewing Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  7. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  8. Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  9. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  10. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026